 Home > Active Ingredient News > Blood System > CJASN: Roxastat can effectively correct anemia in non-dialysis-dependent CKD patients without increasing the risk of cardiovascular events

CJASN: Roxastat can effectively correct anemia in non-dialysis-dependent CKD patients without increasing the risk of cardiovascular events

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

compound non examples

benefits non gmo

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Roxadustat is an effective reversible hypoxia-inducible factor-prolyl hydroxylase inhibitor, which can simulate the body's natural response to hypoxia and stimulate a coordinated erythropoiesis response, including erythropoietin production Increase, decrease of heparin level, increase of iron supply

This study aims to analyze research data on three Rocha Division for his non-dialysis dependent CKD patients with CKD-related anemia 3, evaluate Rosa orlistat vs Placebo effect and heart blood vessel safety

Heart blood vessels

The subjects in these three double-blind trials are all CKD patients with CKD-related anemia who do not require dialysis.

Cardiovascular event myocardial infarction stroke

Changes in the average hemoglobin level of the two groups of patients

A total of 4277 nondialysis-dependent CKD patients were randomly divided into rosastat group (n=2391) and placebo group (n=1886)

During weeks 28-52, compared with the placebo group, the average hemoglobin level of patients in the rosastat group improved from baseline regardless of whether salvage treatment was performed .

Risk ratio of cardiovascular events between the two groups

Compared with placebo, roxastat did not increase the risk of MACE (HR 1.

The results of this study show that rosastat can effectively increase the hemoglobin level of non-dialysis-dependent CKD patients, correct anemia, and reduce the need for blood transfusion without increasing the risk of MACE

Roxastat can effectively increase the hemoglobin level of non-dialysis-dependent CKD patients, correct anemia, and reduce the need for blood transfusion without increasing the risk of MACE

Original source:

Robert Provenzano, Lynda Szczech, Robert Leong, et al.

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Dabigatran etexilate

CAS No.: 211915-06-9

pharmaceutical grade

$100/KG FOB

100% Safe customs clearance high quality Caffeic acid CAS 331-39-5 with Best Price Caffeic acid

CAS No.: 331-39-5

Pharmacy Grade

$4-5/MT FOB

Dabigatran Etexilate Mesylate CAS 872728-81-9

CAS No.: 872728-81-9

Pharmacy Grade

$88-98/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.